Monsanto Co. acquired Beeologics, a startup that researches and develops biological tools for targeted pest and disease control and protecting bee health.
Beelogics is dedicated to restoring bee health and protecting the future of insect pollination. While its primary goal is to control the Colony Collapse Disorder (CCD) and Israeli Acute Paralysis Virus (IAPV) infection crises, Beeologics’ mission is to become the guardian of bee health worldwide. Through continuous research, scientific innovation, and a focus on applicable solutions, Beeologics is developing a line of RNAi-based products to specifically address the long-term well being of the bees. Monsanto said that work will continue under its ownership.
Beeologics’ expertise will allow Monsanto to further explore the use of biologicals in agriculture, the company said.
Monsanto said it will support the Beeologics team and its Technology Advisory Board in advancing its technology pipeline.
Miami, Fla,-based Beeologics also has an office in Israel. The acquisition of Beelogics will help shore up the company’s biological research on pest control, particularly to help address the long-term well being of bees.
Creve Coeur-based agriculture and tech company Monsanto, which is led by Chairman, President and CEO Hugh Grant, reported $10.5 billion in 2010 revenue and this is Monsanto’s first acquisition of a pest control biotech company.